RESUMO
Metal-organic framework (MOF) nanoparticles have recently emerged as a promising vehicle for drug delivery with high porosity and feasibility. However, employing a MOF-based drug delivery system remains a challenge due to the difficulty in controlling interfaces of particles in a biological environment. In this paper, protein corona-blocked Zr6 -based MOF (PCN-224) nanoparticles are presented for targeted cancer therapy with high efficiency. The unmodified PCN-224 surface is precoated with glutathione transferase (GST)-fused targetable affibody (GST-Afb) proteins via simple mixing conjugations instead of chemical modifications that can induce the impairment of proteins. GST-Afb proteins are shown to stably protect the surface of PCN-224 particles in a specific orientation with GST adsorbed onto the porous surface and the GST-linked Afb posed outward, minimizing the unwanted interfacial interactions of particles with external biological proteins. The Afb-directed cell-specific targeting ability of particles and consequent induction of cell death is demonstrated both in vitro and in vivo by using two kinds of Afb, which targets the surface membrane receptor, human epidermal growth factor receptor 2 (HER2) or epidermal growth factor receptor (EGFR). This study provides insight into the way of regulating the protein-adhesive surface of MOF nanoparticles and designing a more effective MOF-hosted targeted delivery system.
Assuntos
Estruturas Metalorgânicas , Nanopartículas , Neoplasias , Humanos , Estruturas Metalorgânicas/metabolismo , Sistemas de Liberação de Medicamentos , Neoplasias/tratamento farmacológico , Proteínas de MembranaRESUMO
Targeted delivery along with controlled drug release is considered crucial in development of a drug delivery system (DDS) for efficient cancer treatment. In this paper, we present a strategy to obtain such a DDS by utilizing disulfide-incorporated mesoporous organosilica nanoparticles (MONs), which were engineered to minimize the surface interactions with proteins for better targeting and therapeutic performance. That is, after MONs were loaded with a chemodrug doxorubicin (DOX) through the inner pores, their outer surface was treated for conjugation to the glutathione-S-transferase (GST)-fused cell-specific affibody (Afb) (GST-Afb). These particles exhibited prompt responsivity to the SS bond-dissociating glutathione (GSH), which resulted in considerable degradation of the initial particle morphology and DOX release. As the protein adsorption to the MON surface appeared largely reduced, their targeting ability with GSH-stimulated therapeutic activities was demonstrated in vitro by employing two kinds of the GST-Afb protein, which target human cancer cells with the surface membrane receptor, HER2 or EGFR. Compared with unmodified control particles, the presented results show that our system can significantly enhance cancer-therapeutic outcomes of the loaded drug, offering a promising way of designing a more efficacious DDS.
Assuntos
Nanopartículas , Neoplasias , Humanos , Portadores de Fármacos/uso terapêutico , Proteínas de Membrana/metabolismo , Proteínas de Membrana/uso terapêutico , Sistemas de Liberação de Medicamentos/métodos , Nanopartículas/metabolismo , Doxorrubicina/uso terapêutico , Glutationa/metabolismo , Neoplasias/tratamento farmacológico , Oxirredução , Dióxido de Silício/uso terapêutico , Porosidade , Liberação Controlada de FármacosRESUMO
For efficient drug delivery, stable encapsulation of a large amount of anticancer drugs is crucial, not to mention cell-specific delivery. Among many possible nanocarriers, mesoporous silica nanoparticles are versatile frameworks that satisfy those requirements owing to their characteristic internal pores with a large surface area and a tunable surface composition. By using a noncovalent post-modification strategy, MSN-based drug delivery systems with enhanced therapeutic efficiency can be prepared in a simple one-pot process by loading small anticancer drugs in the unmodified mesopores and by subsequently blocking the drug-loaded pores with a stimuli-responsive polymer gatekeeper. For targeted delivery, drug-loaded MSNs can be functionalized with suitable targeting components such as targeting ligands or artificial protein corona. This mini-review highlights the recent research in which MSN-supported nanocarriers are designed, synthesized, and characterized to possess a high drug loading capacity and encapsulation stability along with targeting capability for more efficient cancer treatment.